When was Vitalis founded?

Vitalis was founded in 2012 and raised its 1st funding round within a year of its incorporation.

Where is Vitalis located?

Vitalis is headquartered in New York City, United States.

How many employees does Vitalis have?

As of Jul 01, 2024, the latest employee count at Vitalis is 2.

Is Vitalis a funded company?

Vitalis is a funded company, having raised a total of $474K across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Oct 22, 2012.

When was the latest funding round of Vitalis?

Vitalis' latest funding was a $***** Series A round on Dec 13, 2022, with participation from 0 investor. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $182M in funding in 2026 to date.

Where does Vitalis rank among its competitors?

Vitalis ranks 1030th amongst 2721 active competitors, of which 703 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Vor Biopharma, which secured $150M in Dec, 2025.

Who are the top competitors of Vitalis?

Vitalis' top competitors include argenx, Alector and Synthego. Among them, Vor Biopharma secured the most recent funding round in December, 2025.

Vitalis - 2026 Company Profile, Team, Funding & Competitors

Company Details

Pharmaceutical company developing innovative therapies using VTS-Aspirin platform for multiple therapeutic areas. Focused on improving patient lives, the company leverages existing medications to discover innovative treatments. Their research aims to change the paradigm of patient treatment, initially targeting multiple sclerosis, post-operative pain (non-opioid), and dyslipidemia. The company is committed to developing patient-centric therapies that improve disease treatment with fewer side effects and a higher quality of life. They are leveraging their VTS-Aspirin platform to overcome the limitations of existing drugs and enhance patient experience. The company's culture is rooted in serving patients and working on their behalf, with a focus on innovation and patient well-being.

Website: vitalispharma.com
Email ID: *****@vitalispharma.com

Key Metrics

Founded Year

2012

Location

New York City, United States

Stage

Series A

Total Funding

$474K in 2 rounds

Latest Funding Round

Series A, Dec 13, 2022, $*****

Ranked

1030^th among 2721 active competitors

Employee Count

2 as on Jul 01, 2024

Similar Companies

Alector & 3522 more

View Vitalis' full profile

Vitalis has raised a total funding of $474K over 2 rounds. Its first funding round was on Oct 22, 2012.

Here is the list of recent funding rounds of Vitalis:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 13, 2022	7384385	Series A	6067034	6338804	4476843	6834907
Oct 22, 2012	4370762	Seed	3043851	6264561	7186373	3452080

Access funding benchmarks and valuations. Sign up today!

View details of Vitalis's funding rounds and investors

The founders of Vitalis is Joseph Habboushe.

Here are the details of Vitalis' key team members:

Joseph Habboushe: Founder of Vitalis.
Contact Info: 1 email address

View details of Vitalis's Founder profiles and Board Members

Vitalis' employee count trend

Vitalis has 2 employees as of Jul 24. Here is Vitalis's employee count trend over the years:

Uncover Vitalis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Vitalis include argenx, Alector and Synthego. Here is the list of Top 10 competitors of Vitalis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Omnes Capital & 20 others	75/100
2nd	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	72/100
3rd	Synthego 2012, Redwood City (United States), Acquired	Developer of CRISPR-engineered cell and gene therapies	$460M	8VC, RA Capital Management & 30 others	71/100
4th	Tenaya Therapeutics 2016, San Francisco (United States), Public	Developer of regenerative and gene therapeutics for heart failure	$248M	RA Capital Management, RTW Investments & 7 others	70/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	69/100
6th	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
7th	Vor Biopharma 2019, Cambridge (United States), Public	Developer of therapeutics to treat acute myeloid leukemia	$152M	NEXTBio, Mingxin Capital & 10 others	68/100
8th	Avidity Biosciences 2012, San Diego (United States), Acquired	RNA therapeutics innovator targeting muscle and other diseases with AOC platform	$143M	RTW Investments, Takeda Ventures & 19 others	68/100
9th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Citadel, Fidelity Investments & 14 others	67/100
10th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 16 others	67/100
1030th	Vitalis 2012, New York City (United States), Series A	Pharmaceutical company developing innovative therapies using VTS-Aspirin platform for multiple therapeutic areas	$474K	-	32/100